Section 1 of 4Overview

Overview

An approved biologic fertility medicine standardized by FSH and LH activity; it is a mixture, not one chemically defined peptide.

Primary regulatory source

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

Section 2 of 4Identity and mechanism

Identity and mechanism

Its gonadotropin activity drives ovarian follicular development during assisted reproductive technology.

Menotropins is a biologic mixture standardized by FSH and LH activity; assigning one molecular formula or PubChem structure would be misleading.

Section 3 of 4Regulatory label facts

Regulatory label facts

FDA (United States; assisted reproductive technology).

The dose below reproduces a regulator-approved label; it is not a treatment recommendation. Menopur label: an individualized IVF protocol starting at 225 IU subcutaneously daily from cycle day 2 or 3, adjusted after 5 days; maximum 450 IU/day and 20 treatment days.

Section 4 of 4Safety boundary

Safety boundary

Ovarian hyperstimulation syndrome, thromboembolism, multiple gestation and pregnancy complications are major risks. Ultrasound and estradiol monitoring are integral, not optional extras.

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.